NASDAQ:EDSA Edesa Biotech Earnings Date & Estimates $2.17 +0.11 (+5.34%) Closing price 04:00 PM EasternExtended Trading$2.06 -0.11 (-5.07%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Edesa Biotech is estimated to report earnings on Friday, December 11, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateDecember 11, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Edesa BiotechEdesa Biotech is expected to post earnings of -$0.58 per share. In the same quarter a year earlier Edesa Biotech reported $0.53 per share on revenue of $247.15 thousand. Edesa Biotech last reported on August 13, 2026, posting -$0.60 per share and missing the -$0.4350 consensus estimate. Edesa Biotech has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.58Prior-Year EPS$0.53Prior-Year Revenue$247.15 thousandExpected EPS Growth-209.4%Recent Track RecordLast ReportedQ3 2026Last Quarter EPS-$0.60 (Missed by -$0.1650)EPS Beat Rate3 of last 8 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Edesa Biotech Earnings FAQ When does Edesa Biotech report earnings? Edesa Biotech (NASDAQ:EDSA) is estimated to report earnings on Friday, December 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Edesa Biotech? Analysts expect Edesa Biotech to post earnings of -$0.58 per share for the quarter. Edesa Biotech Earnings HeadlinesEdesa Receives EU Orphan Drug Designation For ARDS Therapy ParidiprubartNovember 17 at 1:33 PM | rttnews.comEdesa Biotech Receives European Commission Orphan Designation for Paridiprubart in ARDSNovember 17 at 9:51 AM | quiverquant.comQMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 19 at 1:00 AM | Weiss Ratings (Ad)Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European CommissionNovember 17 at 9:25 AM | globenewswire.comHealthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also GainNovember 9, 2026 | rttnews.comEdesa Biotech Stock Jumps 39% On Japan Licensing DealNovember 9, 2026 | rttnews.comSee More Edesa Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email. Email Address About Edesa BiotechEdesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. The company’s work centers on biologic drug candidates designed to address conditions with limited treatment options. Its pipeline has included EB01, a topical treatment candidate for allergic contact dermatitis, and EB05, an antibody candidate being investigated for acute respiratory distress syndrome. These programs are in development and are not approved treatments. Edesa is based in Markham, Ontario, Canada, and conducts clinical development of its candidates for potential use in international markets.View Edesa Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.